Basisstatistiken
| LEI | 54930033FJRNEYBW0L25 |
| CIK | 1796280 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to ORIC Pharmaceuticals, Inc.
SEC Filings (Chronological Order)
Auf dieser Seite finden Sie eine vollständige, chronologische Liste der SEC-Einreichungen, mit Ausnahme der Eigentumseinreichungen, die wir an anderer Stelle bereitstellen.
| May 4, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39269 ORIC PHARMACEUTICALS, INC. |
|
| May 4, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2026 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commission |
|
| May 4, 2026 |
Exhibit 99.1 ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates Announced selection of rinzimetostat RP3D in combination with darolutamide for Himalayas-1 Phase 3 global registrational trial in post-abiraterone mCRPC, expected to initiate in 1H 2026 Reported rinzimetostat data in post-abiraterone mCRPC supporting potential best-in-disease profile, including |
|
| April 28, 2026 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro |
|
| April 28, 2026 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| April 28, 2026 |
UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION Washington,D.C.20549 FORM10-K (MarkOne) ☒ ANNUALREPORTPURSUANTTOSECTION13OR15(d)OFTHESECURITIESEXCHANGEACTOF1934 ForthefiscalyearendedDecember31,2025 OR ☐ TRANSITIONREPORTPURSUANTTOSECTION13OR15(d)OFTHESECURITIESEXCHANGEACTOF1934 Forthetransitionperiodfrom to CommissionFileNumber:001-39269 ORICPHARMACEUTICALS,INC. (ExactnameofRegistrantasspecifiedinitsC |
|
| March 31, 2026 |
EX-99.1 Exhibit 99.1 Rinzimetostat Dose Optimization Data Update March 31, 2026 Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including statements regarding ORIC Pharmaceuticals, Inc.’s (“ORIC”, “we”, “us” or “our”) future fin |
|
| March 31, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 31, 2026 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commissio |
|
| February 23, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39269 ORIC PHARMACEU |
|
| February 23, 2026 |
Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 Oric Pharmaceuticals, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, $0.0001 par value, reserved for issuance pursuant to the 2020 Equity Incentive Plan Other 2, |
|
| February 23, 2026 |
Exhibit 10.10 ORIC PHARMACEUTICALS, INC. AMENDED AND RESTATED OUTSIDE DIRECTOR COMPENSATION POLICY Originally effective as of April 23, 2020, as amended by the Board of Directors through December 17, 2025. ORIC Pharmaceuticals, Inc. (the “Company”) believes that providing cash and equity compensation to its members of the Board of Directors (the “Board,” and members of the Board, the “Directors”) |
|
| February 23, 2026 |
Exhibit 99.1 ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Updates Reported rinzimetostat (formerly ORIC-944) Phase 1b data that continue to demonstrate potential best-in-class efficacy and safety in mCRPC; selected provisional RP2Ds and initiated dose optimization in combination with AR inhibitors Presented potential best-in-class enozertinib Ph |
|
| February 23, 2026 |
As filed with the Securities and Exchange Commission on February 23, 2026 S-8 As filed with the Securities and Exchange Commission on February 23, 2026 Registration No. |
|
| February 23, 2026 |
Up to $200,000,000 Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-277829 PROSPECTUS SUPPLEMENT (To Prospectus dated March 11, 2024) Up to $200,000,000 Common Stock We have previously entered into an Open Market Sale AgreementSM (sales agreement) with Jefferies LLC (Jefferies) relating to the sale of shares of our common stock offered by this prospectus supplement and the accompanying p |
|
| February 23, 2026 |
Calculation of Filing Fee Tables S-3 Oric Pharmaceuticals, Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward |
|
| February 23, 2026 |
ORIC PHARMACEUTICALS, INC. INSIDER TRADING POLICY (As amended through February 10, 2025) Exhibit 19.1 ORIC PHARMACEUTICALS, INC. INSIDER TRADING POLICY (As amended through February 10, 2025) A. POLICY OVERVIEW ORIC Pharmaceuticals, Inc. (together with any subsidiaries, collectively the “Company”) has adopted this Insider Trading Policy (the “Policy”) to help you comply with the federal and state securities laws and regulations that govern trading in securities and to help the Company |
|
| February 23, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2026 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commi |
|
| February 23, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 23, 2026 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commis |
|
| December 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 6, 2025 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commiss |
|
| December 8, 2025 |
EX-99.1 Exhibit 99.1 Enozertinib (ORIC-114) Program Update December 6, 2025 Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including statements regarding ORIC Pharmaceuticals, Inc.’s (“ORIC”, “we”, “us” or “our”) future financi |
|
| November 13, 2025 |
EX-99.1 ORIC-944 Dose Exploration Data Update November 13, 2025 Exhibit 99.1 Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including statements regarding ORIC Pharmaceuticals, Inc.’s (“ORIC”, “we”, “us” or “our”) future financ |
|
| November 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39269 ORIC PHARMACEUTICALS, INC. |
|
| November 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2025 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commi |
|
| November 13, 2025 |
Exhibit 99.1 ORIC® Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Clinical and Operational Updates Announced completion of dose exploration portion of ORIC-944 Phase 1b clinical trial and presented data that continues to demonstrate potential best-in-class efficacy and safety Bolstered leadership team with the appointment of Kevin Brodbeck, PhD, as Chief Technical Office |
|
| November 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 13, 2025 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commis |
|
| October 6, 2025 |
144 0001695028 XXXXXXXX LIVE 0001796280 Oric Pharmaceuticals, Inc. 001-39269 240 E. Grand Ave 2nd Floor San Francisco CA 94080 6503885600 Dominic Piscitelli Officer Common J.P. Morgan Securities LLC 390 Madison Avenue 6th Floor New York NY 10017 50000 725000 97122987 10/06/2025 Nasdaq Common 10/06/2025 Stock Option Exercise Issuer N 50000 10/06/2025 Cash Y The sales under this filing are from Cash |
|
| September 22, 2025 |
144 0001608936 XXXXXXXX LIVE 0001796280 Oric Pharmaceuticals, Inc. 001-39269 240 E. Grand Ave 2nd Floor San Francisco CA 94080 6503885600 Jacob Chacko Director Officer Common J.P. Morgan Securities LLC 390 Madison Avenue 6th Floor New York NY 10017 250000 2625000 97122987 09/22/2025 Nasdaq Common 05/11/2022 Open Market Purchase See Nature of Acquisition N 250000 05/11/2022 Cash Y 09/22/2025 06/21/ |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39269 ORIC PHARMACEUTICALS, INC. |
|
| August 12, 2025 |
Exhibit 99.1 ORIC® Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Updates Reported potentially best-in-class clinical efficacy and safety data from ongoing Phase 1b trial of ORIC-944 in combination with AR inhibitors for the treatment of patients with mCRPC Strengthened cash position with $244 million gross proceeds from top-tier healthcare specialist investors acros |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commiss |
|
| June 24, 2025 |
ORIC Pharmaceuticals, Inc. 19,230,845 Shares of Common Stock 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-287949 PROSPECTUS ORIC Pharmaceuticals, Inc. 19,230,845 Shares of Common Stock This prospectus relates to the offer and resale from time to time of up to 19,230,845 shares of our common stock, par value $0.0001 per share (the “Shares”), by the selling stockholders identified in this prospectus, including their transferee |
|
| June 17, 2025 |
ORIC Pharmaceuticals, Inc. 240 E. Grand Ave, 2nd Floor South San Francisco, California 94080 CORRESP ORIC Pharmaceuticals, Inc. 240 E. Grand Ave, 2nd Floor South San Francisco, California 94080 June 17, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Tyler Howes Re: ORIC Pharmaceuticals, Inc. Registration Statement on Form S-3 File No. 333-287949 Acceleration Request Requested Date: June 20, 2025 R |
|
| June 16, 2025 |
June 16, 2025 Jacob Chacko, M.D. Chief Executive Officer ORIC Pharmaceuticals, Inc. 240 E. Grand Ave, 2nd Floor South San Francisco, CA 94080 Re: ORIC Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed June 11, 2025 File No. 333-287949 Dear Jacob Chacko M.D.: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 4 |
|
| June 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 11, 2025 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commission |
|
| June 11, 2025 |
As filed with the Securities and Exchange Commission on June 11, 2025 Table of Contents As filed with the Securities and Exchange Commission on June 11, 2025 Registration No. |
|
| June 11, 2025 |
EX-FILING FEES Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-3 (Form Type) ORIC Pharmaceuticals, Inc. |
|
| May 28, 2025 |
Securities Purchase Agreement, dated May 23, 2025 Exhibit 10.1 ORIC PHARMACEUTICALS, INC. SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (the “Agreement”) is made as of May 23, 2025 (the “Effective Date”), by and among ORIC Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the purchasers whose names and addresses are set forth on the signature pages hereof (each, a “Purchaser” and, collectively, the “Purchasers” |
|
| May 28, 2025 |
Exhibit 99.2 ORIC® Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients with mCRPC Broad and deep PSA responses achieved, with 59% PSA50 response rate (confirmed rate of 47%, and one additional response pending confirmation) and 24% PSA90 response rate (all co |
|
| May 28, 2025 |
Exhibit 4.1 THESE SECURITIES REPRESENTED HEREBY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE BUT HAVE BEEN OR WILL BE ISSUED IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND, ACCORDINGLY, MAY NOT BE TRANSFERRED UNLESS (i) S |
|
| May 28, 2025 |
Exhibit 99.1 ORIC® Pharmaceuticals Announces $125 Million Private Placement Financing Financing led by SR One and includes participation from new and existing investors, including Point72, Viking Global Investors, Venrock Healthcare Capital Partners, New Enterprise Associates (NEA), Nextech, Vivo Capital, and NEXTBio Capital Pro forma cash and investments expected to fund current operating plan in |
|
| May 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 23, 2025 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commission |
|
| May 5, 2025 |
Exhibit 99.1 ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates Announced focused registrational clinical development plans for lead programs, extended cash runway, and accelerated/augmented corporate milestones Presented preclinical data supporting potential best-in-class profile of ORIC-944 in combination with AR inhibitors to treat prostate cancer at the |
|
| May 5, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2025 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commission |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39269 ORIC PHARMACEUTICALS, INC. |
|
| April 23, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| April 23, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORMlO-K (Mark One) ~ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR 0 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 F or the transition period from to Commission File Numbe r : 001-39269 ORIC PHARMAC |
|
| March 20, 2025 |
As filed with the Securities and Exchange Commission on March 20, 2025 As filed with the Securities and Exchange Commission on March 20, 2025 Registration No. |
|
| March 20, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) ORIC Pharmaceuticals, Inc. |
|
| March 14, 2025 |
Amended and Restated 2022 Inducement Equity Incentive Plan, and form agreements thereunder. Exhibit 10.1 ORIC PHARMACEUTICALS, INC. AMENDED AND RESTATED 2022 INDUCEMENT EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals entering into employment with the Company or any Parent or Subsidiary of the Company. The Plan permi |
|
| March 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2025 ORIC Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39269 47-1787157 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| February 25, 2025 |
Exhibit 99.1 ORIC® Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones Anticipated registrational development plans for ORIC-944 and ORIC-114 prioritized to focus on indications with strongest clinical validation and highest unmet need ORIC-944 initiation of first Phase 3 trial in mCRPC expected in 1H |
|
| February 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 25, 2025 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commis |
|
| February 18, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2025 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commi |
|
| February 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39269 ORIC PHARMACEU |
|
| February 18, 2025 |
Amended and Restated Outside Director Compensation Policy Exhibit 10.10 ORIC PHARMACEUTICALS, INC. AMENDED AND RESTATED OUTSIDE DIRECTOR COMPENSATION POLICY Originally effective as of April 23, 2020, as amended by the Board of Directors through December 12, 2024. ORIC Pharmaceuticals, Inc. (the “Company”) believes that providing cash and equity compensation to its members of the Board of Directors (the “Board,” and members of the Board, the “Directors”) |
|
| February 18, 2025 |
Exhibit 99.1 ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates Reported encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with androgen receptor inhibitors in patients with mCRPC Entered into clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC-114 in c |
|
| February 18, 2025 |
Insider Trading Policy, as amended Exhibit 19.1 ORIC PHARMACEUTICALS, INC. INSIDER TRADING POLICY (As amended through February 10, 2025) A. POLICY OVERVIEW ORIC Pharmaceuticals, Inc. (together with any subsidiaries, collectively the “Company”) has adopted this Insider Trading Policy (the “Policy”) to help you comply with the federal and state securities laws and regulations that govern trading in securities and to help the Company |
|
| February 12, 2025 |
Exhibit 99 Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. |
|
| January 13, 2025 |
Exhibit 99.1 Company Overview January 2025 Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including statements regarding ORIC Pharmaceuticals, Inc.’s (“ORIC”, “we”, “us” or “our”) future financial condition, results of operatio |
|
| January 13, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 13, 2025 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commiss |
|
| November 14, 2024 |
ORIC / ORIC Pharmaceuticals, Inc. / Nextech Crossover I GP S.a r.l. - SC 13G/A Passive Investment SC 13G/A 1 tm2427660d3sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ORIC Pharmaceuticals, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 68622P109 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statem |
|
| November 14, 2024 |
ORIC / ORIC Pharmaceuticals, Inc. / EcoR1 Capital, LLC Passive Investment SC 13G/A 1 oric13ga5.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5) ORIC Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 68622P109 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the app |
|
| November 14, 2024 |
ORIC / ORIC Pharmaceuticals, Inc. / COLUMN GROUP II, LP - SC 13G/A Passive Investment SC 13G/A 1 d851421dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* ORIC PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 68622P109 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement |
|
| November 13, 2024 |
SC 13G/A 1 p24-3281sc13ga.htm ORIC PHARMACEUTICALS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Oric Pharmaceuticals, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 68622P109 (CUSIP Number) September 30, 2024 (Date of event which requires filing of this sta |
|
| November 12, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commi |
|
| November 12, 2024 |
ORIC / ORIC Pharmaceuticals, Inc. / FMR LLC Passive Investment SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.6 ORIC PHARMACEUTICALS INC COMMON STOCK Cusip #68622P109 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #68622P109 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 4,377,417 Item 6: 0 Item 7: 4,378,819 Item 8: 0 It |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39269 ORIC PHARMACEUTICALS, INC. |
|
| November 12, 2024 |
Exhibit 99.1 ORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates Presented preclinical data further supporting the potential best-in-class profile of ORIC-114 to treat EGFR exon 20 insertions and other atypical mutations at the EORTC-NCI-AACR Conference Announced clinical collaborations with multiple strategic partners to support ongoing trial evaluating ORIC |
|
| November 8, 2024 |
ORIC / ORIC Pharmaceuticals, Inc. / BlackRock, Inc. Passive Investment SC 13G 1 us68622p1093110824.txt us68622p1093110824.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) ORIC PHARMACEUTICALS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 68622P109 - (CUSIP Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| October 22, 2024 |
ORIC / ORIC Pharmaceuticals, Inc. / BlackRock, Inc. Passive Investment SC 13G 1 us68622p1093102224.txt us68622p1093102224.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) ORIC PHARMACEUTICALS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 68622P109 - (CUSIP Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| August 12, 2024 |
Exhibit 99.1 ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates Initiated dosing of ORIC-944 in combinations with NUBEQA® (darolutamide) and ERLEADA® (apalutamide) in the ongoing Phase 1b trial for prostate cancer Entered into clinical trial collaboration and supply agreements with Bayer and Johnson & Johnson to support the ongoing Phase 1b trial of ORIC-944 |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39269 ORIC PHARMACEUTICALS, INC. |
|
| August 12, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2024 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commiss |
|
| June 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 12, 2024 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commission |
|
| May 6, 2024 |
Amended and Restated Outside Director Compensation Policy Exhibit 10.2 ORIC PHARMACEUTICALS, INC. AMENDED AND RESTATED OUTSIDE DIRECTOR COMPENSATION POLICY Originally effective as of April 23, 2020, as amended by the Board of Directors through March 26, 2024. ORIC Pharmaceuticals, Inc. (the “Company”) believes that providing cash and equity compensation to its members of the Board of Directors (the “Board,” and members of the Board, the “Directors”) repr |
|
| May 6, 2024 |
Exhibit 99.1 ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates Initiated three ORIC-114 Phase 1b expansion cohorts in NSCLC patients with EGFR exon 20 insertion, HER2 exon 20 insertion, or EGFR atypical mutations; updated Phase 1b data expected in the first half of 2025 Presented initial ORIC-944 Phase 1b monotherapy data demonstrating potential best-in-clas |
|
| May 6, 2024 |
Exhibit 10.1 AMENDMENT NO. 1 TO THE LICENSE AND COLLABORATION AGREEMENT THIS AMENDMENT NO. 1 TO THE LICENSE AND COLLABORATION AGREEMENT (this “Amendment No. 1”), effective March 20, 2024 (the “Amendment No. 1 Effective Date”), is entered into by and between Voronoi Inc., a limited corporation duly established under the Republic of Korea’s commercial code, having offices at S. 18th F, Songdogwahak- |
|
| May 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2024 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commission |
|
| May 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39269 ORIC PHARMACEUTICALS, INC. |
|
| April 24, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| April 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 24, 2024 |
UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION Washington,D.C.20549 FORM10-K (MarkOne) ☒ ANNUALREPORTPURSUANTTOSECTION13OR15(d)OFTHESECURITIESEXCHANGEACTOF1934 ForthefiscalyearendedDecember31,2023 OR ☐ TRANSITIONREPORTPURSUANTTOSECTION13OR15(d)OFTHESECURITIESEXCHANGEACTOF1934 Forthetransitionperiodfrom to CommissionFileNumber:001-39269 ORICPHARMACEUTICALS,INC. (ExactnameofRegistrantasspecifiedinitsC |
|
| March 29, 2024 |
Amended and Restated 2022 Inducement Equity Incentive Plan, and form agreements thereunder Exhibit 10.1 ORIC PHARMACEUTICALS, INC. AMENDED AND RESTATED 2022 INDUCEMENT EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals entering into employment with the Company or any Parent or Subsidiary of the Company. The Plan permi |
|
| March 29, 2024 |
As filed with the Securities and Exchange Commission on March 29, 2024 As filed with the Securities and Exchange Commission on March 29, 2024 Registration No. |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2024 ORIC Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39269 47-1787157 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 29, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) ORIC Pharmaceuticals, Inc. |
|
| March 11, 2024 |
Exhibit 99.1 ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates Presented initial Phase 1b data from three clinical programs that support potential best in class profiles, with ORIC-944 and ORIC-114 prioritized for further advancement towards registrational studies Initiation of combination study of ORIC-944 with AR inhibitor(s) in metastatic p |
|
| March 11, 2024 |
As filed with the Securities and Exchange Commission on March 11, 2024 Table of Contents As filed with the Securities and Exchange Commission on March 11, 2024 Registration No. |
|
| March 11, 2024 |
Exhibit 97.1 ORIC PHARMACEUTICALS, INC. COMPENSATION RECOVERY POLICY As adopted on September 14, 2023 ORIC Pharmaceuticals, Inc. (the “Company”) is committed to strong corporate governance. As part of this commitment, the Company’s Board of Directors (the “Board”) has adopted this clawback policy called the Compensation Recovery Policy (the “Policy”). The Policy is intended to further the Company’ |
|
| March 11, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2024 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commissi |
|
| March 11, 2024 |
ORIC / ORIC Pharmaceuticals, Inc. / FMR LLC Passive Investment SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.5 ORIC PHARMACEUTICALS INC COMMON STOCK Cusip #68622P109 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #68622P109 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 5,092,788 Item 6: 0 Item 7: 5,094,729 Item 8: 0 It |
|
| March 11, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) ORIC Pharmaceuticals, Inc. |
|
| March 11, 2024 |
Exhibit 4.2 ORIC PHARMACEUTICALS, INC. INDENTURE Dated as of [, 20] [], as Trustee TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 Incorporation by Reference of Trust Indenture Act 5 Section 1.4 Rules of Construction 5 ARTICLE II THE SECURITIES 5 Section 2.1 Issuable in Series 5 Section 2.2 Establis |
|
| March 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39269 ORIC PHARMACEU |
|
| February 14, 2024 |
ORIC / ORIC Pharmaceuticals, Inc. / EcoR1 Capital, LLC Passive Investment SC 13G/A 1 oric13ga4.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4) ORIC Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 68622P109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appr |
|
| February 13, 2024 |
ORIC / ORIC Pharmaceuticals, Inc. / ALKEON CAPITAL MANAGEMENT LLC Passive Investment SC 13G/A 1 oric13ga2024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Oric Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 68622P109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the a |
|
| February 13, 2024 |
ORIC / ORIC Pharmaceuticals, Inc. / Prosight Management, LP - SC 13G/A Passive Investment SC 13G/A 1 d723724dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ORIC PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 68622P109 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) |
|
| February 9, 2024 |
ORIC / ORIC Pharmaceuticals, Inc. / FMR LLC Passive Investment SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.4 ORIC PHARMACEUTICALS INC COMMON STOCK Cusip #68622P109 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #68622P109 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 7,000,212 Item 6: 0 Item 7: 7,002,108 Item 8: 0 It |
|
| February 7, 2024 |
ORIC / ORIC Pharmaceuticals, Inc. / BlackRock Inc. Passive Investment SC 13G/A 1 us68622p1093020724.txt us68622p1093020724.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) ORIC PHARMACEUTICALS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 68622P109 - (CUSIP Number) January 31, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriat |
|
| February 6, 2024 |
ORIC / ORIC Pharmaceuticals, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment SC 13G/A 1 ORICSC13GA.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) ORIC PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 68622P109 (CUSIP Number) DECEMBER 31, 2023 (Date of event which requires filing of this statement) Check the app |
|
| February 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ORIC Pharmaceuticals, Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 68622P109 (CUSIP Number) January 22, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| January 31, 2024 |
ORIC Pharmaceuticals, Inc. 240 E. Grand Ave, 2nd Floor South San Francisco, California 94080 ORIC Pharmaceuticals, Inc. 240 E. Grand Ave, 2nd Floor South San Francisco, California 94080 January 31, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Tim Buchmiller, Staff Attorney Re: ORIC Pharmaceuticals, Inc. Registration Statement on Form S-3 File No. 333-276719 Acceleration Request Requested Date: |
|
| January 31, 2024 |
United States securities and exchange commission logo January 31, 2024 Jacob M. Chacko, M.D. President and Chief Executive Officer Oric Pharmaceuticals, Inc. 240 E. Grand Ave, 2nd Floor South San Francisco, California 94080 Re: Oric Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed January 26, 2024 File No. 333-276719 Dear Jacob M. Chacko: This is to advise you that we have not review |
|
| January 30, 2024 |
ORIC / ORIC Pharmaceuticals, Inc. / VIKING GLOBAL INVESTORS LP - SC 13G Passive Investment SC 13G 1 ef20020178sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d- 1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* ORIC Pharmaceuticals, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Sec |
|
| January 29, 2024 |
ORIC / ORIC Pharmaceuticals, Inc. / BlackRock Inc. Passive Investment SC 13G 1 us68622p1093012924.txt us68622p1093012924.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) ORIC PHARMACEUTICALS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 68622P109 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| January 26, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-3 (Form Type) ORIC Pharmaceuticals, Inc. |
|
| January 26, 2024 |
As filed with the Securities and Exchange Commission on January 26, 2024 Table of Contents As filed with the Securities and Exchange Commission on January 26, 2024 Registration No. |
|
| January 25, 2024 |
EX-99.A 2 d709301dex99a.htm EX-99.A EXHIBIT A AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of Common Stock of ORIC Pharmaceuticals, Inc. Date: January 25, 2024 FRAZIER LIFE SCIENCES PUBLI |
|
| January 25, 2024 |
SC 13G 1 d709301dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ORIC Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 68622P109 (CUSIP Number) January 23, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa |
|
| January 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 20, 2024 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commiss |
|
| January 22, 2024 |
EX-99.1 Exhibit 99.1 ORIC Pharmaceuticals Announces $125 Million Private Placement Financing Funding from new and existing investors including Viking Global Investors, Commodore Capital, Frazier Life Sciences, Venrock Healthcare Capital Partners, New Enterprise Associates (NEA), and Nextech Pro forma cash and investments expected to fund current operating plan into late 2026 SOUTH SAN FRANCISCO an |
|
| January 22, 2024 |
Securities Purchase Agreement, dated January 20, 2024 EX-10.1 Exhibit 10.1 ORIC PHARMACEUTICALS, INC. STOCK PURCHASE AGREEMENT This Stock Purchase Agreement (the “Agreement”) is made as of January 20, 2024 (the “Effective Date”), by and among ORIC Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the purchasers whose names and addresses are set forth on the signature pages hereof (each, a “Purchaser” and, collectively, the “Purchaser |
|
| January 9, 2024 |
Exhibit 99.1 Company Overview January 2024 Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including statements regarding ORIC Pharmaceuticals, Inc.’s (“ORIC”, “we”, “us” or “our”) future financial condition, results of operatio |
|
| January 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 9, 2024 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commissi |
|
| December 26, 2023 |
ORIC Pharmaceuticals, Inc. 240 E. Grand Ave, 2nd Floor South San Francisco, California 94080 ORIC Pharmaceuticals, Inc. 240 E. Grand Ave, 2nd Floor South San Francisco, California 94080 December 26, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Lauren Sprague Hamill, Senior Counsel Re: ORIC Pharmaceuticals, Inc. Registration Statement on Form S-3 File No. 333-276077 Acceleration Request Requested |
|
| December 22, 2023 |
United States securities and exchange commission logo December 22, 2023 Dominic Piscitelli Chief Financial Officer Oric Pharmaceuticals, Inc. |
|
| December 15, 2023 |
As filed with the Securities and Exchange Commission on December 15, 2023 S-3 Table of Contents As filed with the Securities and Exchange Commission on December 15, 2023 Registration No. |
|
| December 15, 2023 |
CALCULATION OF FILING FEE TABLES Form S-3 (Form Type) ORIC Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1)(2) Proposed Maximum Offering Price Per Unit (3) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees |
|
| December 11, 2023 |
Exhibit 99.1 Initial Phase 1 Dose Escalation Data for ORIC-533 in Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity and Strong Safety Profile Supporting Potential for Combination Development Preliminary evidence of clinical antimyeloma activity, including reduction in paraprotein, demonstrated in multiple patients Clean safety profile with only Grade 1 and 2 treatment related adv |
|
| December 11, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 11, 2023 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commis |
|
| November 6, 2023 |
Exhibit 99.1 ORIC Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates Presented initial Phase 1b data for ORIC-114 in patients with EGFR and HER2 Exon 20 mutated NSCLC demonstrating potential best-in-class profile Initial Phase 1b data for ORIC-533 in patients with multiple myeloma to be presented at the 65th ASH Annual Meeting being held December 9-12, 2023 Initia |
|
| November 6, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2023 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commis |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39269 ORIC PHARMACEUTICALS, INC. |
|
| October 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 21, 2023 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commiss |
|
| October 23, 2023 |
EX-99.1 Exhibit 99.1 Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class Profile CNS activity observed at multiple dose levels, including the first reported confirmed CNS complete response by an EGFR exon 20 inhibitor in a patient with documented untreated brain metastases Systemic responses observed at multiple dos |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39269 ORIC PHARMACEUTICALS, INC. |
|
| August 10, 2023 |
Exhibit 99.1 ORIC Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates Initial Phase 1b clinical data for ORIC-114 in EGFR/HER2-mutated cancers to be presented at the ESMO Congress being held October 20-24, 2023 Initial Phase 1b clinical data expected for ORIC-533 in multiple myeloma in fourth quarter of 2023 and ORIC-944 in prostate cancer in first quarter of 2024 |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 10, 2023 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commissi |
|
| July 7, 2023 |
ORIC / ORIC Pharmaceuticals Inc / Nextech Crossover I GP S.a r.l. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ORIC Pharmaceuticals, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 68622P109 (CUSIP Number) June 27, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| June 27, 2023 |
Securities Purchase Agreement, dated June 24, 2023 EX-10.1 Exhibit 10.1 ORIC PHARMACEUTICALS, INC. SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (the “Agreement”) is made as of June 24, 2023 (the “Effective Date”), by and among ORIC Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the purchasers whose names and addresses are set forth on the signature pages hereof (each, a “Purchaser” and, collectively, the “Pu |
|
| June 27, 2023 |
ORIC Pharmaceuticals Announces $85 Million Private Placement Financing EX-99.1 Exhibit 99.1 ORIC Pharmaceuticals Announces $85 Million Private Placement Financing June 26, 2023 Financing led by Nextech and includes participation from EcoR1 Capital, Frazier Life Sciences, Venrock Healthcare Capital Partners, and Boxer Capital Pro forma cash and investments expected to fund current operating plan into late 2025 SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 26, 2023 ( |
|
| June 27, 2023 |
EX-4.1 Exhibit 4.1 THESE SECURITIES REPRESENTED HEREBY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE BUT HAVE BEEN OR WILL BE ISSUED IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND, ACCORDINGLY, MAY NOT BE TRANSFERRED UNLES |
|
| June 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 24, 2023 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commission |
|
| June 15, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 14, 2023 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commission |
|
| June 12, 2023 |
ORIC / ORIC Pharmaceuticals Inc / Prosight Management, LP - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ORIC PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 68622P109 (CUSIP Number) May 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designat |
|
| June 12, 2023 |
JOINT FILING AGREEMENT June 9, 2023 EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT June 9, 2023 Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended (the “Act”), and the rules and regulations thereunder, each party hereto hereby agrees to the joint filing, on behalf of each of them, of any filing required by such party under Section 13 or Section 16 of the Act or any rule or regulation thereunder (includin |
|
| May 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 8, 2023 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commission F |
|
| May 8, 2023 |
Exhibit 99.1 ORIC Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates Initial Phase 1b data for three ongoing clinical trials expected in second half of 2023: ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2-mutated cancers, and ORIC-944 in prostate cancer Preclinical data for ORIC-944 and PLK4 program presented at the 2023 AACR Annual Meeting Cash and investmen |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39269 ORIC PHARMACEUTICALS, INC. |
|
| April 26, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro |
|
| April 26, 2023 |
DEF 14A 1 d447451ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as |
|
| April 26, 2023 |
UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION Washington,D.C.20549 FORM10-K (MarkOne) ☒ ANNUALREPORTPURSUANTTOSECTION13OR15(d)OFTHESECURITIESEXCHANGEACTOF1934 ForthefiscalyearendedDecember31,2022 OR ☐ TRANSITIONREPORTPURSUANTTOSECTION13OR15(d)OFTHESECURITIESEXCHANGEACTOF1934 Forthetransitionperiodfrom to CommissionFileNumber:001-39269 ORICPHARMACEUTICALS,INC. (ExactnameofRegistrantasspecifiedinitsC |
|
| March 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 20, 2023 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commissio |
|
| March 24, 2023 |
EX-3.1 Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF ORIC PHARMACEUTICALS, INC. (as amended and restated on March 20, 2023) TABLE OF CONTENTS Page ARTICLE I—CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II—MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES 2 2.5 NOTICE OF STOCKHOLDERS’ MEETINGS 9 2.6 QU |
|
| March 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 16, 2023 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commissio |
|
| March 16, 2023 |
Exhibit 99.1 ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Updates Initial Phase 1b data for three ongoing clinical trials expected in second half of 2023: ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2-mutated cancers, and ORIC-944 in prostate cancer Received $25 million equity investment from Pfizer, and entered into clinical development co |
|
| March 16, 2023 |
As filed with the Securities and Exchange Commission on March 16, 2023 S-8 As filed with the Securities and Exchange Commission on March 16, 2023 Registration No. |
|
| March 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39269 ORIC PHARMACEU |
|
| March 16, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) ORIC Pharmaceuticals, Inc. |
|
| February 13, 2023 |
ORIC / ORIC Pharmaceuticals Inc / ALKEON CAPITAL MANAGEMENT LLC Passive Investment SC 13G/A 1 oric13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Oric Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 68622P109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the approp |
|
| February 10, 2023 |
ORIC / ORIC Pharmaceuticals Inc / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) ORIC Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 68622P109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 9, 2023 |
ORIC / ORIC Pharmaceuticals Inc / FMR LLC Passive Investment SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.3 ORIC PHARMACEUTICALS INC COMMON STOCK Cusip #68622P109 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #68622P109 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 4,016,344 Item 6: 0 Item 7: 4,016,608 Item 8: 0 It |
|
| February 6, 2023 |
ORIC / ORIC Pharmaceuticals Inc / VICTORY CAPITAL MANAGEMENT INC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ( Amendment No.1)* Oric Pharmaceuticals Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 68622P109 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| January 20, 2023 |
ORIC / ORIC Pharmaceuticals Inc / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ORIC PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 68622P109 (CUSIP Number) JANUARY 13, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant t |
|
| January 9, 2023 |
EX-99.1 2 d448025dex991.htm EX-99.1 Exhibit 99.1 ORIC Pharmaceuticals Provides Corporate Update and Highlights Key Upcoming Milestones Initial Phase 1b data for three ongoing clinical trials expected in second half of 2023: ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2-mutated cancers, and ORIC-944 in prostate cancer Development candidate selected for PLK4 synthetic lethal breast cancer prog |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 9, 2023 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commissi |
|
| December 29, 2022 |
ORIC / ORIC Pharmaceuticals Inc / PFIZER INC - SC 13G ORIC PHARMACEUTICALS Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* ORIC PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 68622P109 (CUSIP Number) December 23, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| December 27, 2022 |
ORIC / ORIC Pharmaceuticals Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 4 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* ORIC Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 68622P 109 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VI LLC OrbiMed Capital LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739- |
|
| December 27, 2022 |
EX-99.1 2 ss1628562ex9901.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated December 22, 2022, with respect to the common stock of ORIC Pharmaceuticals, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Each o |
|
| December 21, 2022 |
EX-99.2 Exhibit 99.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 21, 2022, between ORIC Pharmaceuticals, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), and Pfizer Inc., a corporation organized under the laws of the State of Delaware (the “Purchaser”). WHEREAS, subject to the terms and conditions |
|
| December 21, 2022 |
5,376,344 Shares of Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-255833 PROSPECTUS SUPPLEMENT (To Prospectus dated April 27, 2022) 5,376,344 Shares of Common Stock We are offering 5,376,344 shares of our common stock directly to the investor, Pfizer Inc., in this offering at a price per share of $4.65. This offering is being made without an underwriter or a placement agent and we are |
|
| December 21, 2022 |
EX-99.1 Exhibit 99.1 ORIC Pharmaceuticals Announces Clinical Development Collaboration with Pfizer for ORIC-533 in Multiple Myeloma and Concurrent $25 Million Equity Investment by Pfizer ORIC and Pfizer have entered into a clinical development collaboration for a Phase 2 study of ORIC-533 in combination with elranatamab in multiple myeloma Jeff Settleman, Ph.D., Chief Scientific Officer, Pfizer On |
|
| December 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 21, 2022 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commis |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39269 ORIC PHARMACEUTICALS, INC. |
|
| November 7, 2022 |
Exhibit 99.1 ORIC Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Update Initial Phase 1b data for three ongoing clinical studies expected to be reported in 1H 2023: ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2-mutated cancers, and ORIC-944 in prostate cancer Ongoing clinical development of ORIC-114 expanded with FDA clearance of US IND Preclinical data on ORIC- |
|
| November 7, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 7, 2022 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commiss |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39269 ORIC PHARMACEUTICALS, INC. |
|
| August 11, 2022 |
Exhibit 99.1 ORIC Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Update Three ongoing single agent Phase 1 programs, ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2 cancers, and ORIC-944 in prostate cancer, all expected to report initial data in 1H 2023 Cash and investments of $237.8 million expected to fund current operating plan into 2H 2024 SOUTH SAN FRANCISCO |
|
| August 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 11, 2022 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commissi |
|
| July 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO/A (Amendment No. 1) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 ORIC PHARMACEUTICALS, INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, $0.0001 par value (Title of Class of Securities) 68622P109 (CUSIP Number of |
|
| July 8, 2022 |
ORIC / ORIC Pharmaceuticals Inc / BlackRock Inc. Passive Investment us68622p1093070822.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) ORIC PHARMACEUTICALS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 68622P109 - (CUSIP Number) June 30, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t |
|
| June 21, 2022 |
Email to All Eligible Employees. Exhibit (a)(1)(B) Email to All Eligible Employees From: Jacob M. Chacko, M.D., President and Chief Executive Officer, ORIC Pharmaceuticals, Inc. To: All Eligible Employees Date: June 21, 2022 Subject: LAUNCH OF ORIC?S STOCK OPTION EXCHANGE PROGRAM Dear ORIC Eligible Employee: You are receiving this email because you are eligible to participate in a voluntary, one-time stock option exchange offer ( |
|
| June 21, 2022 |
Form of Notice Email to Eligible Employees Regarding Expiration of Offering Period. Exhibit (a)(1)(F) Form of Notice Email to Eligible Employees Regarding Expiration of Offering Period From: Jacob M. |
|
| June 21, 2022 |
Exhibit (a)(1)(E) Form of Reminder Email The ORIC Pharmaceuticals, Inc. (?ORIC?) offer to exchange certain outstanding stock options for new stock options (referred to as the ?Offer?) currently is still open. Please note that the Offer will expire at 9:00 p.m., Pacific Time, on July 20, 2022, unless we extend the Offer. The Offer deadline will be strictly enforced, so we encourage you to give your |
|
| June 21, 2022 |
Form of Confirmation to Eligible Employees. Exhibit (a)(1)(D) Form of Confirmation to Eligible Employees ORIC Pharmaceuticals, Inc. |
|
| June 21, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form TO-I (Form Type) ORIC Pharmaceuticals, Inc. |
|
| June 21, 2022 |
Screenshots from Offer Website. Exhibit (a)(1)(H) |
|
| June 21, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 ORIC PHARMACEUTICALS, INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, $0.0001 par value (Title of Class of Securities) 68622P109 (CUSIP Number of Class of Securities? Underlying C |
|
| June 21, 2022 |
Election Terms and Conditions. Exhibit (a)(1)(C) ORIC PHARMACEUTICALS, INC. OFFER TO EXCHANGE CERTAIN OUTSTANDING STOCK OPTIONS FOR NEW STOCK OPTIONS ELECTION TERMS AND CONDITIONS 1. I agree that my decision to accept or reject the Offer with respect to some or all of my eligible option grants is entirely voluntary and is subject to the terms and conditions of the Offer. 2. I understand that I may change my election at any time |
|
| June 21, 2022 |
Offer to Exchange Certain Outstanding Stock Options for New Stock Options, dated June 21, 2022. Table of Contents Exhibit (a)(1)(A) ORIC PHARMACEUTICALS, INC. OFFER TO EXCHANGE CERTAIN OUTSTANDING STOCK OPTIONS FOR NEW STOCK OPTIONS This document constitutes part of the prospectus relating to the securities that have been registered under the Securities Act of 1933, as amended. The prospectus relates to the ORIC Pharmaceuticals, Inc. 2020 Equity Incentive Plan and the ORIC Pharmaceuticals, I |
|
| June 21, 2022 |
Exhibit (a)(5) From: Dominic Piscitelli, CFO To: Certain Investors Subject: ORIC Employee Stock Option Exchange As you may have seen, today we filed a tender offer related to a voluntary stock option exchange for our employees. |
|
| June 21, 2022 |
Stock Option Exchange June 22, 2022 Exhibit (a)(1)(G) Stock Option Exchange Overview What are we doing and why? Options are a key component of our incentive and retention program, and we have offered them broadly, at all employee levels, since ORIC?s founding We believe options encourage employees to act like owners of the business by: Motivating us to work toward our collective success Rewarding |
|
| June 21, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 17, 2022 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commission |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39269 ORIC PHARMACEUTICALS, INC. |
|
| May 9, 2022 |
License Agreement between the registrant and Mirati Therapeutics, Inc., dated as of August 3, 2020. Exhibit 10.2 CERTAIN INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. OMISSIONS ARE DESIGNATED AS [***]. LICENSE AGREEMENT THIS LICENSE AGREEMENT (this ?Agreement?), entered into as of August 3, 2020 (the ?Effective Date?), is entered into by and between Mirati Therapeutics, Inc., a Dela |
|
| May 9, 2022 |
Exhibit 99.1 ORIC Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Update Three ongoing single agent Phase 1 programs, ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2 cancers, and ORIC-944 in prostate cancer, all expected to report initial data in 1H2023 Four preclinical presentations at the 2022 AACR Annual Meeting Cash and investments of $256.2 million expected to |
|
| May 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 9, 2022 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commission F |
|
| May 9, 2022 |
Exhibit 10.3 CERTAIN INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. OMISSIONS ARE DESIGNATED AS [***]. LICENSE AND COLLABORATION AGREEMENT BETWEEN ORIC PHARMACEUTICALS, INC. AND VORONOI INC. TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 3 ARTICLE II GRANT OF LICENSE 14 ARTICLE III GOVER |
|
| April 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 27, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi |
|
| March 22, 2022 |
As filed with the Securities and Exchange Commission on March 22, 2022 As filed with the Securities and Exchange Commission on March 22, 2022 Registration No. |
|
| March 22, 2022 |
As filed with the Securities and Exchange Commission on March 22, 2022. Table of Contents As filed with the Securities and Exchange Commission on March 22, 2022. |
|
| March 22, 2022 |
Filing Fee Disclosure and Payment Methods Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) ORIC Pharmaceuticals, Inc. |
|
| March 21, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) ORIC Pharmaceuticals, Inc. |
|
| March 21, 2022 |
Exhibit 99.1 ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Update Announces decision to discontinue development of ORIC-101 Company will focus on advancing its three single agent Phase 1 programs, ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2 cancers, and ORIC-944 in prostate cancer, with initial data expected from the three programs in 1H 2 |
|
| March 21, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 21, 2022 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commissio |
|
| March 21, 2022 |
Description of the Registrant’s securities Exhibit 4.3 DESCRIPTION OF THE REGISTRANT?S CAPITAL STOCK REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following descriptions of our capital stock and certain provisions of our amended and restated certificate of incorporation and amended and restated bylaws are summaries and are qualified by reference to the amended and restated certificate of incorporation and the |
|
| March 21, 2022 |
Amended and Restated Outside Director Compensation Policy Exhibit 10.10 ORIC PHARMACEUTICALS, INC. AMENDED AND RESTATED OUTSIDE DIRECTOR COMPENSATION POLICY Originally effective as of April 23, 2020, as amended by the Board of Directors as of March 16, 2022 (the ?Effective Date?). ORIC Pharmaceuticals, Inc. (the ?Company?) believes that providing cash and equity compensation to its members of the Board of Directors (the ?Board,? and members of the Board, |
|
| March 21, 2022 |
Table of Contents As filed with the Securities and Exchange Commission on March 21, 2022. |
|
| March 21, 2022 |
Fourth Quarter and Full Year 2021 Financial Results and Operational Update March 21, 2022 Exhibit 99. |
|
| March 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39269 ORIC PHARMACEU |
|
| March 21, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 21, 2022 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commissio |
|
| March 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2022 ORIC Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39269 47-1787157 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 4, 2022 |
Exhibit 10.1 ORIC PHARMACEUTICALS, INC. 2022 INDUCEMENT EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals entering into employment with the Company or any Parent or Subsidiary of the Company. The Plan permits the grant of Nonst |
|
| February 14, 2022 |
ORIC / ORIC Pharmaceuticals Inc / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) ORIC Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 68622P109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 11, 2022 |
ORIC / ORIC Pharmaceuticals Inc / COLUMN GROUP II, LP - SC 13G/A Passive Investment SC 13G/A 1 d314465dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ORIC PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 68622P109 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) |
|
| February 9, 2022 |
ORIC / ORIC Pharmaceuticals Inc / FMR LLC Passive Investment SCHEDULE 13G Amendment No. 2 ORIC PHARMACEUTICALS INC COMMON STOCK Cusip #68622P109 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #68622P109 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 1,283,814 Item 6: 0 Item 7: 5,907,279 Item 8: 0 Item 9: 5,907,279 Item |
|
| February 3, 2022 |
ORIC / ORIC Pharmaceuticals Inc / BlackRock Inc. Passive Investment us68622p1093020322.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) ORIC PHARMACEUTICALS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 68622P109 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| February 2, 2022 |
ORIC / ORIC Pharmaceuticals Inc / VICTORY CAPITAL MANAGEMENT INC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ( Amendment No.)* Oric Pharmaceuticals Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 68622P109 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| January 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 10, 2022 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commiss |
|
| January 10, 2022 |
Exhibit 99.1 ORIC Pharmaceuticals Provides Corporate Update and Highlights Key Upcoming Milestones ORIC-101 program on track for updates from both ongoing clinical trials in first half of 2022 Initial Phase 1b data from ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2 cancers and ORIC-944 in prostate cancer expected in first half of 2023 Cash and investments of $280.8 million expected to fund o |
|
| November 10, 2021 |
ORIC Pharmaceuticals Appoints Angie You, Ph.D., to its Board of Directors Exhibit 99.1 ORIC Pharmaceuticals Appoints Angie You, Ph.D., to its Board of Directors SOUTH SAN FRANCISCO and SAN DIEGO, CA ? November 10, 2021 ? ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the appointment of Angie You, Ph.D., to its board of directors. Dr. You curr |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 9, 2021 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commiss |
|
| November 8, 2021 |
Exhibit 99.1 ORIC Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Update Initial clinical data from Phase 1b trial of ORIC-101 in combination with enzalutamide and preclinical data on ORIC-114 presented at AACR-NCI-EORTC Update on oral CD73 inhibitor program to be presented at the American Society of Hematology (ASH) Annual Meeting and Phase 1 trial initiation of singl |
|
| November 8, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 8, 2021 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commiss |
|
| November 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39269 ORIC PHARMACEUTICALS, INC. |
|
| November 8, 2021 |
2020 Employee Stock Purchase Plan, and form agreements thereunder Exhibit 10.2 ORIC PHARMACEUTICALS, Inc. 2020 EMPLOYEE STOCK PURCHASE PLAN 1. Purpose. The purpose of the Plan is to provide employees of the Company and its Designated Companies with an opportunity to purchase Common Stock through accumulated Contributions. The Company intends for the Plan to have two components: a component that is intended to qualify as an ?employee stock purchase plan? under Se |
|
| October 7, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 7, 2021 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commissi |
|
| October 7, 2021 |
EX-99.1 2 d181647dex991.htm EX-99.1 Exhibit 99.1 ORIC Pharmaceuticals Presents Initial Clinical Data from Phase 1b Trial of ORIC-101 in Combination with Enzalutamide and Preclinical Data on ORIC-114 at AACR-NCI-EORTC ORIC-101 and enzalutamide combination regimen at the recommended Phase 2 dose was well tolerated; adverse events generally consistent with single agent enzalutamide ORIC-101 plasma co |
|
| August 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 17, 2021 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commissi |
|
| August 16, 2021 |
ORIC Pharmaceuticals Appoints Steven L. Hoerter to its Board of Directors EX-99.1 3 d127312dex991.htm EX-99.1 Exhibit 99.1 ORIC Pharmaceuticals Appoints Steven L. Hoerter to its Board of Directors SOUTH SAN FRANCISCO and SAN DIEGO, CA – August 16, 2021 – ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the appointment of 25-year industry vetera |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 12, 2021 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commissi |
|
| August 16, 2021 |
Exhibit 10.1 FIRST AMENDMENT TO LEASE This FIRST AMENDMENT TO LEASE (?First Amendment?) is made and entered into as of August 12, 2021, by and between BRITANNIA POINTE GRAND LIMITED PARTNERSHIP, a Delaware limited partnership (?Landlord?), and ORIC PHARMACEUTICALS, INC., a Delaware corporation (?Tenant?). R E C I T A L S : A. Landlord and Tenant are parties to the Lease dated June 5, 2015 (the ?Le |
|
| August 12, 2021 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated August 12, 2021, with respect to the ordinary shares of ORIC Pharmaceuticals, Inc. |
|
| August 12, 2021 |
ORIC / ORIC Pharmaceuticals Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 3 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* ORIC Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 68622P 109 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VI LLC OrbiMed Capital LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739- |
|
| August 10, 2021 |
EX-99.1 2 oric-20210810ex991.htm EX-99.1 Exhibit 99.1 ORIC Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Update ORIC-101 on track for initial Phase 1b data readout in prostate cancer in 2H21 ORIC-533 IND cleared by FDA; initiation of Phase 1 trial expected in 2H21 IND/CTA filings for ORIC-944 and ORIC-114 expected in 2H21 Cash and investments of $305.9 million, expe |
|
| August 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39269 ORIC PHARMACEUTICALS, INC. |
|
| August 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 10, 2021 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commissi |
|
| July 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 8, 2021 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commission |
|
| July 8, 2021 |
EX-99.1 2 d128943dex991.htm EX-99.1 Exhibit 99.1 ORIC Pharmaceuticals Announces FDA Clearance of IND Application for ORIC-533, a Highly Potent, Orally Bioavailable Small Molecule CD73 Inhibitor ORIC expects to initiate single agent clinical trial in an undisclosed tumor type in 2H21 ORIC-533 IND filing is the first of three IND/CTA filings expected in 2021 SOUTH SAN FRANCISCO and SAN DIEGO, CA – J |
|
| July 8, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 28, 2021 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commission |
|
| June 21, 2021 |
Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 16, 2021 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commission |
|
| June 21, 2021 |
EX-99.1 2 d183984dex991.htm EX-99.1 Exhibit 99.1 ORIC Pharmaceuticals Reports Initial Clinical Data Being Presented at ASCO from Phase 1b Trial of ORIC-101 in Combination with Nab-Paclitaxel June 2, 2021 Initial safety data showed combination regimen at the recommended Phase 2 dose was well tolerated; treatment-related adverse events primarily Grade 1 or 2, with no treatment-related discontinuatio |
|
| May 6, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 6, 2021 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commission F |
|
| May 6, 2021 |
Table of Contents As filed with the Securities and Exchange Commission on May 6, 2021. |
|
| May 6, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 6, 2021 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commission F |
|
| May 6, 2021 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-255833 CALCULATION OF REGISTRATION FEE Title of Securities to be Registered Proposed Maximum Aggregate Offering Price Amount of Registration Fee Common stock, par value $0.0001 per share $ 150,000,000 $ 16,365 (1) (1) The filing fee is calculated and being paid pursuant to Rule 457(r) under the Securities Act of 1933, as amend |
|
| May 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39269 ORIC PHARMACEUTICALS, INC. |
|
| May 6, 2021 |
EX-4.2 2 d179648dex42.htm EX-4.2 Exhibit 4.2 ORIC PHARMACEUTICALS, INC. INDENTURE Dated as of [, 20] [], as Trustee TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 Incorporation by Reference of Trust Indenture Act 5 Section 1.4 Rules of Construction 5 ARTICLE II THE SECURITIES 5 Section 2.1 Issuable |
|
| May 6, 2021 |
EX-99.1 2 oric-ex9916.htm EX-99.1 EXHIBIT 99.1 ORIC Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Update Lead program ORIC-101 on track for two initial Phase 1b data readouts in 2021 Three IND/CTA filings for ORIC-533, -944, and -114 expected in 2021 SOUTH SAN FRANCISCO and SAN DIEGO, CA – May 6, 2021 – ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage onco |
|
| May 6, 2021 |
EX-1.1 2 d116190dex11.htm EX-1.1 Exhibit 1.1 OPEN MARKET SALE AGREEMENTSM May 6, 2021 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: ORIC Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), |
|
| April 26, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi |
|
| April 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| March 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39269 ORIC PHARMACEU |
|
| March 23, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 23, 2021 ORIC Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39269 47-1787157 (State or other jurisdiction of incorporation) (Commissio |
|
| March 23, 2021 |
As filed with the Securities and Exchange Commission on March 23, 2021 Registration No. |
|
| March 23, 2021 |
EX-99.1 2 oric-ex9917.htm EX-99.1 Exhibit 99.1 ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Update Lead program ORIC-101 on track for two initial data readouts in 2021 Three IND/CTA filings for ORIC-533, -944, and -114 expected in 2021 Cash, Cash Equivalents and Investments of $293.6 million expected to fund current operations into second half of |
|
| March 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* ORIC Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 68622P 109 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VI LLC OrbiMed Capital LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739- |
|
| March 22, 2021 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated March 19, 2021, with respect to the ordinary shares of ORIC Pharmaceuticals, Inc. |
